INTERNATIONAL PATENT: GENENTECH, INC., F. HOFFMANN-LA ROCHE AG, HOFFMANN-LA ROCHE INC. FILES APPLICATION FOR "SUBCUTANEOUS DOSING OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN FOR USE IN TREATING NON-HODGKIN'S LYMPHOMA"

GENEVA, March 11 -- GENENTECH, INC. (1 DNA WaySouth San Francisco, CA 94080-4990), F. HOFFMANN-LA ROCHE AG (Grenzacherstrasse 1244070 Basel), HOFFMANN-LA ROCHE INC. (150 Clove Road, Overlook at Great Notch, Suite 8Little Falls, NJ 07424) filed a patent application (PCT/US2025/043900) for "SUBCUTANEOUS DOSING OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN FOR USE IN TREATING NON-HODGKIN'S LYMPHOMA" on Aug 28, 2025. With publication no. WO/2026/050474, the details related to the patent application was published on Mar 05, 2026.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): TO, Iris, Tran...